Lizbeth Herrera, APRN
Psychiatric/Mental Health · El Dorado, ARNPI 1043867914
Payments from drug & device makers
Across 65 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$513
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$469
- Otsuka America Pharmaceutical, Inc.$147
- Johnson & Johnson$47
- Axsome Therapeutics, Inc.$33
- Takeda Pharmaceuticals U.S.A., Inc.$25
- plus $37 from 2 others
What the payments were for
- Food & beverage$1,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $513 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $469 |
| Otsuka America Pharmaceutical, Inc. | 8 | $147 |
| Johnson & Johnson | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$1,271 in reported general payments places this provider in the 60th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ziprasidone Hcl | 14 | $808 |
| Hydroxyzine Pamoate | 15 | $503 |
| Aripiprazole | 27 | $414 |
| Quetiapine Fumarate | 46 | $404 |
| Olanzapine | 17 | $360 |
| Duloxetine Hcl | 28 | $350 |
| Lurasidone Hcl | 11 | $247 |
| Fluoxetine Hcl | 35 | $194 |
| Hydroxyzine Hcl | 18 | $186 |
| Donepezil Hcl | 22 | $173 |
| Sertraline Hcl | 19 | $141 |
| Lamotrigine | 19 | $101 |
| Clonazepam | 15 | $88 |
| Trazodone Hcl | 15 | $81 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in El Dorado
- Christie KellerFayetteville$167K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Jennifer PenneFayetteville$11K
- Stephanie ParishSearcy$9K
- Elizabeth HardyTexarkana$8K
- Tammy HawkinsJonesboro$8K
- Cara MeckfesselLittle Rock$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.